Novozymes Biopolymer, part of Novozymes, world leader in bioinnovation,announced winning the Gold Innovation Award at CPhI worldwide conference in Frankfurt, Germany, for its novel form of hyaluronic acid (HA) HyaCare®.
Traditionally, HA is derived from rooster combs or from strains of pathogenic Streptococcal bacteria, which allows for a high degree of contamination by animal proteins, viruses and end toxins present in the bacterial genome. HyaCare is developed under animal-free conditions with no animal derived ingredients used at any stage of the manufacturing process. Novozymes Biopolymerdeveloped this unique non-pathogenic method for producing HA by fermentation of a novel production strain, Bacillus subtilis.
HyaCare is produced using Novozymes Biopolymer patented, advanced and safe fermentation and purification technology which results in a completely pure product. While both rooster comb and Streptococcus derived HAs must be recovered using powerful organic solvents, this product is secreted outside the bacterial cell and can be collected using only water, eliminating the need for organic solvents. HyaCare is used for a wide range of solubility applications in the pharmaceutical sector, including ophthalmology, wound healing and osteoarthritis as well as in cosmetic and anti-wrinkle creams.
see more:Labels: biopolymers
PermaLink - Novozymes Biopolymer's Novel Hyaluronic acid (HA) HyaCare Wins Gold Innovation Award
0 Comments